Program Type: Midwest CEPAC

Transthyretin Amyloid Cardiomyopathy

Sep 2024 | Assessment

Interventions of Interest Transthyretin amyloid cardiomyopathy (ATTR-CM) is a type of heart muscle disease that occurs when amyloid fibrils – clumps of misfolded proteins – are deposited into heart tissue and cause it to stiffen. Eventually, the heart cannot fill properly, leading to shortness of breath, heart failure, and death. For questions please contact Madeline […]

Chronic Obstructive Pulmonary Disease

Jun 2024 | Assessment

Interventions of Interest Chronic obstructive pulmonary disease (COPD) is a group of lung diseases characterized byprogressive and persistent airflow obstruction in the lungs. COPD affects approximately 15.7million people in the United States, with higher rates among non-Hispanic White individuals, Native American individuals, women, and adults older than 65. For questions please contact Liis Shea, Senior […]

Pulmonary Arterial Hypertension

Dec 2023 | Assessment

Interventions of Interest: Independent appraisal committee voted that sotatercept demonstrated a net health benefit when compared to background therapy; sotatercept would achieve common thresholds for cost-effectiveness if priced between $17,900 to $35,400 per year. Final Documents ICER’s Chief Medical Officer, David Rind, MD: “Pulmonary arterial hypertension is a progressive disease that can lead to debilitating […]

Non-Alcoholic Steatohepatitis

Apr 2023 | Assessment

Interventions of Interest: An independent appraisal committee narrowly voted that currently available evidence for resmetirom is adequate to demonstrate a net health benefit over lifestyle management, whereas current evidence for obeticholic acid was deemed inadequate to demonstrate a net health benefit. ICER analyses suggest resmetirom would achieve common thresholds for cost-effectiveness if priced between $39,600 – $50,100 […]

Menopause: Vasomotor Symptoms

Dec 2022 | Assessment

Interventions of Interest: The independent appraisal committee voted that evidence is not yet adequate to demonstrate a net health benefit for fezolinetant when compared to no pharmacological treatment. Using point estimates from short-term clinical trials, analyses suggest this drug would achieve common thresholds for cost-effectiveness if priced between $2,000 – $2,600 per year for women […]

Amyotrophic Lateral Sclerosis (ALS)

Aug 2022 | Assessment

Interventions of Interest: Relyvrio was removed from the market on April 4, 2024. Read ICER’s commentary on Amylyx’s decision to discontinue the drug here. Final Documents ICER’s Chief Medical Officer, David Rind, MD stated: “The votes of the Midwest CEPAC reflected the remaining uncertainties around the benefits of these therapies and the overwhelming certainty that […]

COVID-19

Dec 2022 | Assessment

Interventions of Interest: We have deemed this a “special assessment” since this is an early snapshot of emerging agents in the COVID-19 pipeline. December 2022 Update Dominant viral variants, vaccination/prior infection status, and evidence on Paxlovid continue to evolve, but ICER is presenting an update based on recent evidence to help inform new discussions on […]